BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

778 related articles for article (PubMed ID: 24051084)

  • 1. Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature.
    Ashworth A; Rodrigues G; Boldt G; Palma D
    Lung Cancer; 2013 Nov; 82(2):197-203. PubMed ID: 24051084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer.
    Fleckenstein J; Petroff A; Schäfers HJ; Wehler T; Schöpe J; Rübe C
    BMC Cancer; 2016 Jun; 16():348. PubMed ID: 27255302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer.
    Ashworth AB; Senan S; Palma DA; Riquet M; Ahn YC; Ricardi U; Congedo MT; Gomez DR; Wright GM; Melloni G; Milano MT; Sole CV; De Pas TM; Carter DL; Warner AJ; Rodrigues GB
    Clin Lung Cancer; 2014 Sep; 15(5):346-55. PubMed ID: 24894943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereotactic Ablative Body Radiotherapy (SABR) in Pulmonary Oligometastatic/Oligorecurrent Non-small Cell Lung Cancer Patients: A New Therapeutic Approach.
    Agolli L; Valeriani M; Nicosia L; Bracci S; De Sanctis V; Minniti G; Enrici RM; Osti MF
    Anticancer Res; 2015 Nov; 35(11):6239-45. PubMed ID: 26504057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors.
    Griffioen GH; Toguri D; Dahele M; Warner A; de Haan PF; Rodrigues GB; Slotman BJ; Yaremko BP; Senan S; Palma DA
    Lung Cancer; 2013 Oct; 82(1):95-102. PubMed ID: 23973202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer.
    Juan O; Popat S
    Clin Lung Cancer; 2017 Nov; 18(6):595-606. PubMed ID: 28377206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiosurgery and fractionated stereotactic radiotherapy in oligometastatic/oligoprogressive non-small cell lung cancer patients: Results of a multi-institutional series of 198 patients treated with "curative" intent.
    Buglione M; Jereczek-Fossa BA; Bonù ML; Franceschini D; Fodor A; Zanetti IB; Gerardi MA; Borghetti P; Tomasini D; Di Muzio NG; Oneta O; Scorsetti M; Franzese C; Romanelli P; Catalano G; Dell'Oca I; Beltramo G; Ivaldi GB; Laudati A; Magrini SM; Antognoni P;
    Lung Cancer; 2020 Mar; 141():1-8. PubMed ID: 31926440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome of radical local treatment of non-small cell lung cancer patients with synchronous oligometastases.
    Kwint M; Walraven I; Burgers S; Hartemink K; Klomp H; Knegjens J; Verheij M; Belderbos J
    Lung Cancer; 2017 Oct; 112():134-139. PubMed ID: 29191586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oligo-recurrence predicts favorable prognosis of brain-only oligometastases in patients with non-small cell lung cancer treated with stereotactic radiosurgery or stereotactic radiotherapy: a multi-institutional study of 61 subjects.
    Niibe Y; Nishimura T; Inoue T; Karasawa K; Shioyama Y; Jingu K; Shirato H
    BMC Cancer; 2016 Aug; 16(1):659. PubMed ID: 27542716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consolidative Local Ablative Therapy Improves the Survival of Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated With First-Line EGFR-TKIs.
    Xu Q; Zhou F; Liu H; Jiang T; Li X; Xu Y; Zhou C
    J Thorac Oncol; 2018 Sep; 13(9):1383-1392. PubMed ID: 29852232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The evolving role of radiotherapy in treatment of oligometastatic NSCLC.
    Bergsma DP; Salama JK; Singh DP; Chmura SJ; Milano MT
    Expert Rev Anticancer Ther; 2015; 15(12):1459-71. PubMed ID: 26536370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereotactic radiotherapy in oligometastatic cancer.
    Kennedy TAC; Corkum MT; Louie AV
    Chin Clin Oncol; 2017 Sep; 6(Suppl 2):S16. PubMed ID: 28917254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lung Metastases Treated With Stereotactic Ablative Radiation Therapy in Oligometastatic Colorectal Cancer Patients: Outcomes and Prognostic Factors After Long-Term Follow-Up.
    Agolli L; Bracci S; Nicosia L; Valeriani M; De Sanctis V; Osti MF
    Clin Colorectal Cancer; 2017 Mar; 16(1):58-64. PubMed ID: 27522627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors and management of oligometastatic non-small cell lung cancer.
    Patel AN; Simone CB; Jabbour SK
    Ther Adv Respir Dis; 2016 Aug; 10(4):338-48. PubMed ID: 27060187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addition of radiotherapy to the primary tumour in oligometastatic NSCLC: A systematic review and meta-analysis.
    Petrelli F; Ghidini A; Cabiddu M; Tomasello G; De Stefani A; Bruschieri L; Vitali E; Ghilardi M; Borgonovo K; Barni S; Trevisan F
    Lung Cancer; 2018 Dec; 126():194-200. PubMed ID: 30527187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Might radiation therapy in addition to chemotherapy improve overall survival of patients with non-oligometastatic Stage IV non-small cell lung cancer?: Secondary analysis of two prospective studies.
    Su S; Hu Y; Ouyang W; Ma Z; Li Q; Li H; Wang Y; Wang X; Li T; Li J; Chen M; Lu Y; Bai Y; He Z; Lu B
    BMC Cancer; 2016 Nov; 16(1):908. PubMed ID: 27871270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term Follow-up and Patterns of Recurrence of Patients With Oligometastatic NSCLC Treated With Pulmonary SBRT.
    Hörner-Rieber J; Bernhardt D; Blanck O; Duma M; Eich HT; Gerum S; Gkika E; Hass P; Henkenberens C; Herold HU; Hildebrandt G; Imhoff D; Kahl H; Janssen S; Jurianz K; Krempien R; Lautenschläger SF; Lohaus F; Mueller AC; Petersen C; Sackerer I; Scafa D; Schrade E; Uhlmann L; Wittig A; Guckenberger M
    Clin Lung Cancer; 2019 Nov; 20(6):e667-e677. PubMed ID: 31327644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients.
    Collen C; Christian N; Schallier D; Meysman M; Duchateau M; Storme G; De Ridder M
    Ann Oncol; 2014 Oct; 25(10):1954-1959. PubMed ID: 25114022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of local ablative therapy in oligometastatic non-small-cell lung cancer: hype or hope.
    Bansal P; Rusthoven C; Boumber Y; Gan GN
    Future Oncol; 2016 Dec; 12(23):2713-2727. PubMed ID: 27467543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study.
    Blake-Cerda M; Lozano-Ruíz F; Maldonado-Magos F; de la Mata-Moya D; Díaz-García D; Lara-Mejía L; Zatarain-Barrón ZL; Cuevas-Góngora MF; Barron-Barron F; Corona-Cruz JF; Cabrera-Miranda L; Arroyo-Hernández M; Gerson R; Arrieta O
    Lung Cancer; 2021 Feb; 152():119-126. PubMed ID: 33385737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.